Study Summary
This trial is testing a new drug to see if it is effective, safe, and well tolerated when used in addition to standard care for treating patients.
- Lupus Nephritis
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Weeks 24 and 52
Trial Safety
Phase-Based Safety
Trial Design
5 Treatment Groups
Iptacopan + standard of care (part 2)
1 of 5
Iptacopan + placebo (part 2)
1 of 5
Iptacopan + standard of care (part 1)
1 of 5
Placebo matching iptacopan + standard of care (part 2)
1 of 5
Placebo matching iptacopan + standard of care (part 1)
1 of 5
Active Control
Non-Treatment Group
240 Total Participants · 5 Treatment Groups
Primary Treatment: Iptacopan + standard of care (part 2) · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
To what degree can combining Iptacopan and the established treatment protocol be detrimental to a patient's health?
"Our assessment of Iptacopan + standard of care (part 2) yielded a score of 2; this is because there are no known efficacy data, but safety has been partially verified." - Anonymous Online Contributor
Is there currently an enrollment period for this investigation?
"Confirmed. Medical data available on clinicaltrials.gov states that this trial is still open for participants and was first posted to the site on August 10th 2022, with its latest edit occuring on November 18th 2022." - Anonymous Online Contributor
What is the aggregate number of individuals participating in this scientific investigation?
"Affirmative. Data from clinicaltrials.gov confirms that this trial, whose first posting was on August 10th 2022 is actively recruiting for participants. A total of 240 patients need to be enrolled at 2 distinct medical centres." - Anonymous Online Contributor